CBD Helps With This Rare Blistering Skin Disorder, New Study From Avicanna Shows Promising Results In Epidermolysis Bullosa Treatment

Zinger Key Points
  • CBD-based medicines help ease pain and itching in those with Epidermolysis Bullosa disorder while improving wound healing.
  • Avicanna's study used its RHO Phyto branded Ultra CBD Topical Cream on patients with epidermolysis bullosa.

There is no cure for a rare blistering skin disorder called Epidermolysis Bullosa (EB), but treatments to help alleviate and control the symptoms do exist.  

The growing body of research suggests cannabinoid-based medicines can ease the pain and severe itching in those with this disorder while also improving healing.

Avicanna Inc. AVCN AVCNF 0NN, a biopharma company focused on the development and commercialization of plant-derived CBD products announced it has completed a retrospective observational real-world study using its RHO Phyto branded Ultra CBD Topical Cream, an oil-based 3% CBD localized cream on patients with epidermolysis bullosa.

See also: Game-Changer In Epidermolysis Bullosa Treatment? Cannabis Compound Holds Promise

Led by Elena Pope, MD, M.Sc., FRCPC, head of dermatology at The Hospital for Sick Children in Toronto, the study evaluated the reported and documented responses related to wound healing, pain and itch end points through images for study purposes.

The research included 20 patients with an average age of 17.3 years, including 6 female and 14 male patients. All patients were diagnosed with various subtypes of EB including dystrophic (60%), simplex (30%) and junctional (10%).

Results

The study findings showed that following a month-long application of the 3% CBD cream daily, 55% of patients reported improvement in wound healing while 45% displayed wound stability.

Moreover, self-reported itch and pain scores were reported in 65% and 50% of patients, respectively.

"The use of RHO Phyto branded Ultra CBD Topical Cream is a novel topical therapeutic option for EB patients, providing symptom relief and potentially aiding in wound healing with good tolerability," Dr. Pope said in a press release. "Further prospective studies are needed to substantiate these findings."

Interested in learning more about cannabis innovation? Join us at the 19th Benzinga Cannabis Capital Conference in Chicago this Oct. 8-9. Get your tickets now before prices go up by following this link.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: CannabisNewsEurozoneHealth CareCBD StudyElena PopeEpidermolysis Bullosamanufacturing
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

The Top Cannabis Event In New Jersey

Join the Benzinga Cannabis Market Spotlight in New Jersey on June 17th! Grow your business, raise money and capitalize on the booming NJ recreational market. Don’t miss this must-attend event in New Brunswick. Secure your tickets now. Very few spots are left. Use the code "JAVIER20" for 20% off!


Loading...